Research programme: microbiome therapeutics - KoBioLabs
Alternative Names: KBL-983; KBLP-004Latest Information Update: 08 Sep 2021
At a glance
- Originator KoBioLabs
- Class Bacteria; Hepatoprotectants; Obesity therapies
- Mechanism of Action Bacteria replacements; Microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Non-alcoholic steatohepatitis; Obesity